Dr Reddy's launches generic OTC ophthalmic solution in US market

Dr Reddy's Laboratories has launched a new eye drop in the United States. This over-the-counter solution treats itchy eyes. It is an antihistamine eye drop. The company received approval from the US Food and Drug Administration. This launch expand...

By PTI | Jan 14, 2026, 10.51 PM IST

New Delhi, Dr Reddy's Laboratories on Wednesday said it has launched a generic over-the-counter ophthalmic solution for the treatment of itchy eyes in the US after getting approval from the US Food and Drug Administration.

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 per cent is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.

"This launch adds to our current portfolio in the OTC eye-care space, which includes Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 per cent and 0.1 per cent strengths," Dr Reddy's Laboratories CEO North America Generics Milan Kalawadia said in a statement.

The first-to-market launch is a testament to the company's deep capabilities in bringing store-brand equivalents of OTC brands in the US market, he added.

The Pataday brand recorded sales of around USD 69.9 million in the US for the latest 52-week period ending December 27, 2025, according to NIQ data.

Dr Reddy's shares on Wednesday ended 0.33 per cent down at Rs 1,186.45 apiece on BSE.

Start a SIP with as low as ₹500 with ET Money App!